Brandon Folkes
Stock Analyst at Rodman & Renshaw
(1.91)
# 2,978
Out of 4,711 analysts
47
Total ratings
29.41%
Success rate
-3.15%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMTI Rockwell Medical | Initiates: Buy | $5 | $2.08 | +140.38% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.69 | +225.20% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $2.99 | +201.00% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $10.31 | -12.71% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $1.07 | +647.66% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $8.10 | +97.53% | 6 | Sep 13, 2024 | |
| CRMD CorMedix | Initiates: Buy | $13 | $8.57 | +51.69% | 1 | Aug 26, 2024 | |
| MIST Milestone Pharmaceuticals | Initiates: Buy | $9 | $1.80 | +400.00% | 1 | Aug 22, 2024 | |
| MNKD MannKind | Initiates: Buy | $8 | $6.85 | +16.79% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $4.05 | +72.84% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.58 | +343.04% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.40 | +614.29% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.45 | +2,805.03% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $33.68 | +75.18% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $122.97 | +46.38% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.65 | +3,289.31% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.68 | +92.31% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.71 | +7.71% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $6.50 | +338,361.54% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $29.70 | -25.93% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $720 | $3.22 | +22,260.25% | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $53.35 | -25.02% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $27 → $21 | $0.42 | +4,898.81% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $36.26 | +37.89% | 1 | Jul 12, 2018 |
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $2.08
Upside: +140.38%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $3.69
Upside: +225.20%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $2.99
Upside: +201.00%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $10.31
Upside: -12.71%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $1.07
Upside: +647.66%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.10
Upside: +97.53%
CorMedix
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $8.57
Upside: +51.69%
Milestone Pharmaceuticals
Aug 22, 2024
Initiates: Buy
Price Target: $9
Current: $1.80
Upside: +400.00%
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $6.85
Upside: +16.79%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $4.05
Upside: +72.84%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $1.58
Upside: +343.04%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
Jun 13, 2024
Initiates: Buy
Price Target: $13
Current: $0.45
Upside: +2,805.03%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $33.68
Upside: +75.18%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $122.97
Upside: +46.38%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.65
Upside: +3,289.31%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $4.68
Upside: +92.31%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.71
Upside: +7.71%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $6.50
Upside: +338,361.54%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $29.70
Upside: -25.93%
Jul 30, 2021
Initiates: Overweight
Price Target: $720
Current: $3.22
Upside: +22,260.25%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $53.35
Upside: -25.02%
Mar 5, 2020
Reiterates: Overweight
Price Target: $27 → $21
Current: $0.42
Upside: +4,898.81%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $36.26
Upside: +37.89%